Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective - Sorbonne Université Access content directly
Journal Articles Reports of Practical Oncology & Radiotherapy Year : 2023

Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective

Abstract

Whole brain radiotherapy (WBRT) has long been a key treatment of newly diagnosed primary central nervous system lym- phoma (PCNSL). In the 1990s, the addition of high dose Methotrexate-based induction chemotherapy (HD MTX-based CT) has enabled a drastic improvement in PCNSL patients outcome. However, combined treatment has led to radiation-induced delayed neurotoxicity, especially in older patients. Alternative treatment strategies have been assessed to improve the effi- cacy and neurotoxicity ratio. Nowadays, in the elderly patients WBRT is widely omitted or deferred, and in younger patients WBRT is challenged by high dose chemotherapy with autologous stem cell transplant (HCT-ASCT) for consolidation treat- ment after HD MTX-based CT. In this setting, this review is addressed to clinicians with the aim to summarize the role of WBRT in the treatment of newly diagnosed PCNSL and its perspectives.

Domains

Cancer
Fichier principal
Vignette du fichier
95784-388643-1-PB.pdf (557.21 Ko) Télécharger le fichier
Origin Publication funded by an institution
Licence

Dates and versions

hal-04268581 , version 1 (02-11-2023)

Licence

Identifiers

Cite

Alice Thomas, Caroline Houillier, Delphine Antoni, Khe Hoang Xuan, Carole Soussain, et al.. Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective. Reports of Practical Oncology & Radiotherapy, 2023, 28 (2), pp.271-285. ⟨10.5603/RPOR.a2023.0028⟩. ⟨hal-04268581⟩
6 View
8 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More